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Abstract 
Loss-of-function mutations in the gene encoding GLUT10 are responsible for arterial 
tortuosity syndrome (ATS), a rare connective tissue disorder. In the present study 
GLUT10 mediated dehydroascorbic acid (DAA) transport was investigated, supposing 
its involvement in the pathomechanism. GLUT10 protein produced by in vitro 
translation and incorporated into liposomes efficiently transported DAA. Silencing of 
GLUT10 decreased DAA transport in immortalized human fibroblasts whose plasma 
membrane was selectively permeabilized. Similarly, the transport of DAA through 
endomembranes was markedly reduced in fibroblasts from ATS patients. Re-expression 
of GLUT10 in patients’ fibroblasts restored DAA transport activity. The present results 
demonstrate that GLUT10 is a DAA transporter and DAA transport is diminished in the 
endomembranes of fibroblasts from ATS patients.  
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Introduction 
 
The Major Facilitator Superfamily consists several thousands of membrane transporters, 
including the SLC2A (solute carrier 2A) gene family encoding glucose transporter 
(GLUT) proteins. GLUT family members – presently 14 proteins – are grouped into 
three different classes based on their sequence similarities; GLUT10 encoded by 
SLC2A10 gene belongs to class 3 [1]. Loss-of-function mutations in the SLC2A10 gene 
are responsible for arterial tortuosity syndrome (ATS); however, the precise cellular 
location, the transported ligand(s) and the exact physiological role of GLUT10 have not 
been clarified.  
ATS (OMIM #208050) is a monogenic autosomal recessive heritable connective tissue 
disorder characterized by elongation and generalized tortuosity of the major arteries. 
The clinical phenotype also includes aneurysms of large arteries and stenosis of the 
pulmonary artery. Patients usually present dysmorphic facial features and other 
connective tissue abnormalities such as hyperextensible skin and joint laxity [2-5]. 
Histopathological analysis shows extreme disorganization and fragmentation of elastic 
fibers in the arterial wall [2]. SLC2A10 has been localized to human chromosome 
20q12–q13.1, one of the genomic loci associated with non-insulin-dependent-diabetes-
mellitus (NIDDM), thus SLC2A10 has previously been considered as a candidate gene 
for NIDDM [6]. However, independent studies have failed in confirming any 
association between SLC2A10 mutations and NIDDM [7-9]. Three mechanisms have 
been proposed to explain the link between defective GLUT10 activity and the arterial 
defects described in ATS.  
The first hypothesis, based on the perinuclear localization of GLUT10 in human 
fibroblasts, assumes that the glucose-dependent regulation of gene expression is altered 
in ATS. In particular, since in ATS cells the expression of decorin, a known 
proteoglycan TGFβ signaling inhibitor, was found down-regulated [2], it was supposed 
that the glucose-induced upregulation of decorin is missing in ATS, also explaining the 
upregulation of the TGFβ pathway observed in ATS cells [2].  
The second theory suggests that GLUT10 is involved in transport of  dehydroascorbic 
acid (DAA), the oxidized form of the potent antioxidant ascorbic acid (AA) across the 
mitochondrial membranes, where GLUT10 has been localized with 
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immunofluorescence studies in smooth muscle cells and adipocytes [10]. Upon being 
transported into mitochondrial matrix, DAA is reduced to AA, which can eliminate 
reactive oxygen species (ROS), thereby protecting the cell from oxidative stress. The 
ROS levels in the aortic smooth muscle cells of GLUT10 knock-out mice [10] are 
indeed higher under oxidative stress conditions and their mitochondrial DAA transport 
activity is reduced. However, the relevance of these findings can be questioned as the 
phenotype of the GLUT10 knockout mice is very mild [11] or even normal [12] as 
compared to the human ATS phenotype.  
A third hypothesis, based on our previous works [13-15] has also been proposed [16]. 
According to this hypothesis, GLUT10 acts as a DAA transporter in the endoplasmic 
reticulum (ER) membrane. DAA, in turn, is reduced to AA in the ER lumen, where it 
acts as a cofactor for the hydroxylation of prolyl and lysyl residues by Fe2+/2-
oxoglutarate dependent dioxygenases, a biochemical reaction crucial for collagen and 
elastin maturation and folding. Supporting the hypothesis, it was shown that transiently 
transfected GLUT10-GFP constructs and organelle-specific fluorescent probe ER-
Tracker Blue-White colocalized in rat aortic smooth muscle cells [16]. However, 
transport activities have not been demonstrated in the ER and other subcellular 
compartments. 
As we demonstrated earlier, DAA is imported into the microsomal lumen by a transport 
system sharing the inhibitory properties of GLUTs [13] and DAA-derived AA 
accumulates in the ER lumen [14,15,17]. The transport activity was present in liver 
microsomes [13], but also in microsomes from various non-hepatic tissues/cells, 
including human fibroblasts [15]. 
Up to now, glucose or DAA transporters have not been molecularly characterized in the 
endomembranes. The presence of a glucose transporter has long been supposed as a 
component of the glucose-6-phosphatase system of the ER [18]. This assumption was 
experimentally confirmed by using genetically encoded fluorescence resonance energy 
transfer nanosensors [19]. Glucose transport was shown to be mediated by at least two 
transporters with different characteristics in rat liver microsomes [20]. A possible 
explanation for this heterogeneity is that various plasma membrane GLUT transporters 
function locally during ER-to-plasma membrane transit [21]. Transport of DAA is 
typically mediated by GLUT transporters both in the plasma membrane and 
endomembranes [22]. Therefore, DAA transport in the ER can be also mediated by a 
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GLUT transporter. 
To date, there is no consensus regarding the subcellular localization of GLUT10 and the 
ligand it transports. On the other hand, GLUT10 could excellently act the part of the 
missing glucose/DAA transporter of the ER. Therefore, the aim of the present study was 
to verify the role of GLUT10 as a DAA transporter. Our observations demonstrate that 
GLUT10 is functioning as a DAA transporter and DAA transport activity is diminished 
in the endomembranes of fibroblasts from ATS patients lacking functional GLUT10 
transporter. 
 
 
Materials and Methods 
 
Patients and cell cultures 
Skin fibroblasts from ATS patients and unrelated healthy donors were established from 
skin biopsies as previously reported [2]. Patient 1 (P1) was homozygous for the 
c.1334delG microdeletion [2]; patient 2 (P2) was compound heterozygous for the 
c.1309G>A and the c.1330C>T transitions [23], patient 3 (P3) was homozygous for the 
c.1411+1G>A splicing mutation [24]; and patients 4-8 (P4-P8), members of the same 
family, all bearing the homozygous c.510G>A mutation [2]. Written informed consent 
was obtained from each patient for skin biopsy procedure. This study was approved by 
the medical ethical committee of the University Hospital Spedali Civili of Brescia, Italy 
(in case of P1-P3) and by the Ghent University Hospital, Belgium (for P4-P8), and was 
performed in accordance with the Declaration of Helsinki Principles. 
Dermal fibroblasts cultures were grown in vitro at 37° C in a 5% CO2 atmosphere in 
Earle’s Modified Eagle Medium (MEM) supplemented with 2 mM L-glutamine, 10% 
fetal bovine serum, 100 µg/ml penicillin and streptomycin (Life Technologies, 
Carlsbad, CA, USA). Cells were analyzed at the same in vitro passage number (5th to 
7th). 
 
Page 6 of 26FEBS Letters
For Review Only
 6
Construction of a stable GLUT10 expression vector 
A stable GLUT10 expression vector was generated as previously reported [25]. Briefly, 
the full-length of human SLC2A10 cds (refseq: NM_030777.3) was amplified from total 
RNA of normal skin fibroblasts with the SuperScript III One-Step RT-PCR System and 
inserted into the eukaryotic pEF6/V5-His-TOPO™ expression vector containing the 
blasticidin selectable marker gene and the strong human elongation factor 1α promoter 
(Life Technologies, Carlsbad, CA, USA). This expression vector (pG10) and the empty 
cloning vector (mock) were stable transfected in the skin fibroblasts of P1 using the 
FUGENE 6 liposomal transfection reagent (Roche Applied Science, Mannheim, 
Germany). Selection was achieved by adding selective medium (2 µg/ml of blasticidine) 
that was changed every 3 d until the elimination of all sensitive cells. Established cell 
lines carrying integrated pG10 construct or empty vector were expanded for subsequent 
experiments. 
 
Indirect immunofluorescence analysis 
To analyze the presence and distribution of GLUT10, control, untransfected and mock-
transfected ATS fibroblasts, and ATS cells re-expressing GLUT10 were grown 48 h 
and reacted for 2 min with 3% paraformaldehyde/0.5% Triton, 20 min with 3% 
paraformaldehyde, washed with 100 mM glycine/PBS, blocked for 30 min with 5% 
BSA and immunoreacted overnight at  4° C with 20 µg/ml polyclonal rabbit anti-
GLUT10 antibody (Alpha Diagnostic Int. Inc., San Antonio, TX). After washing in 
PBS, cells were incubated for 1 h at room temperature with the rhodamine-conjugated 
anti-rabbit secondary antibody. The signals were acquired by a CCD black and white 
TV camera (SensiCam-PCO Computer Optics GmbH, Germany) mounted on a Zeiss 
fluorescence Axiovert microscope and digitalized by Image Pro Plus program (Media 
Cybernetics, Silver Spring, MD). The experiments were repeated three times.  
 
Subcellular fractionation of  human  fibroblasts 
Microsomal fraction was prepared from human fibroblasts as reported earlier [26] with 
minor modifications. The trypsinized cells were resuspended in sucrose-HEPES buffer 
(0.34 M sucrose, 10 mM HEPES; pH 7.4) and sonicated 5 times for 15 seconds at 4° C 
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using Sonic 300 Dismembrator (35% pulse cycle). Cell homogenates were centrifuged 
for 10 minutes at 1000 g. The postnuclear supernatant were centrifuged for 20 minutes 
at 18000 g. Microsomes were recovered by ultracentrifugation for 60 minutes at 195000 
g. Pellets were resuspended in 20 mM MOPS buffer (pH 7.2) and maintained in liquid 
N2. 
 
hTERT fibroblast cultures 
BJ-5ta hTERT immortalized fibroblasts from LGC Standards (Teddington, Middlesex, 
UK) were cultured in a 4:1 mixture of Dulbecco’s Modified Eagle Medium (Life 
Technologies, Carlsbad, California, USA) and Medium199 (Life Technologies) 
supplemented with 0.01 mg/ml hygromycin B (Life Technologies), 10% fetal bovine 
serum (Life Technologies) and 1% Antibiotic-Antimycotic (Life Technologies).  All 
cultures were grown in 75 cm2 cell culture flasks (Sigma-Aldrich Co., Saint Louis, 
Missouri, USA) and maintained in humidified incubator at 37° C with a 5% CO2 in air 
atmosphere. 
 
Silencing 
shRNA-mediated knockdown of the SLC2A10 gene was achieved with human GIPZ 
lentiviral shRNAmir constructs containing viral particles (Costume-made by Thermo 
Scientific Open Biosystems). Three different silencing sequences and a scrambled 
sequence were cloned in lentiviral vectors to produce viral particles. Infection of 
hTERT cells was performed according to the manufacturers' instructions (Thermo 
Scientific Open Biosystems - Technical Manual – Expression Arrest GIPZ Lentiviral 
shRNAmir), with a multiplicity of infection (MOI) of 3:1. For stable expression 
experiments, selection of transduced cells was performed with puromycin, starting 48 
hrs after infection. 
 
RNA isolation and PCR analysis 
RNA was isolated using the RNeasy Plus Mini Kit (Qiagen) according to the 
manufacturer’s instructions. 2 µg of RNA were reverse transcribed with SuperScript® 
III First-Strand Synthesis System for RT-PCR (Invitrogen) and random hexamers. 
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Expression levels of SLC2A10 were quantified by fluorescent Real time PCR with a 
DNA engine thermal cycler (MJ Research, Waltham, MA) equipped with Opticon 
Monitor 4 software. Analyses were performed in triplicates in a 25 µl reaction mixture. 
cDNA (1 µl) was amplified with Platinum SYBR Green qPCR SuperMix UDG 
(Invitrogen) and 200 nM of the sense and antisense primers. For SLC2A10, the 
oligonucleotide primers were: sense, 5’ CTTCAACTGGGCGGCCAACCT3’; 
antisense, 5’ CGAGGACAGCGGTCAGTCCGT3’. Amplification protocol was: 95º C 
(10 min), 40 cycles of 95° C (20 s), 55º C (20 s), 72º C (20 s). The PCR amplification 
efficiency was evaluated by serial (10- fold) dilutions of the human cellular cDNA. 
Diluted and undiluted samples were then analyzed in duplicate. Amplification 
efficiency was calculated as reported [27]. The amplification efficiency was more than 
90%. Every assay was run in triplicate and negative controls (no template, template 
produced with no reverse transcriptase enzyme) were always included. In the negative 
controls, no signal was detected in the investigated amplification range (40 cycles). 
 
Western blot analysis  
For Western blot analysis, hTERT cells were subcultured in 6 well plate, and used after 
2-3 d. Confluent wells were washed with PBS and lysed with RIPA buffer (50 mM 
Tris-Cl, pH8, 150 mM NaCl, 1% NP40, 0,1% SDS). Total protein concentration was 
determined by Pierce BCA Protein Assay Kit (Thermo Scientific, Rockford, Illinois, 
USA). Equal protein amounts (15-20 µg) were subjected to 10-12% SDS-PAGE and 
transferred to PVDF membranes by semidry Western blotting.  The membranes were 
blocked in 5% milk or 5% BSA overnight, then probed using specific rabbit polyclonal 
anti-glucose transporter GLUT10 antibody (1:1000; Abcam, Cambridge, UK) and 
GAPDH (1:7500; Santa Cruz Biotechnology, Inc., Dallas, Texas, USA). The Western 
blots were developed using chemiluminescent detection system (Thermo Scientific). 
Protein levels were evaluated through densitometry.  
 
Preparation of cells for transport measurements 
Cells grown in 75 cm2 cell culture flasks, were detached by trypsinization, harvested by 
centrifugation (5 min; 1300 rpm), washed, recentrifuged  and resuspended in sterile 
PBS (2x106 cells/ml).  
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Plasma membrane permeabilized fibroblasts were prepared as described above, except 
that following the last centrifugation step cells were resuspended in MOPS buffer (100 
mM KCl, 20 mM NaCl, 1 mM MgCl2, 20 mM MOPS, pH 7.2). Having counted the 
cells, suspensions were incubated at 4° C in the presence of 1 mM NaN3 and 40 µM 
digitonin until permeabilized (10-20 mins). Plasma membrane permeabilization was 
controlled by trypan blue exclusion. After removal of digitonin by centrifugation, cells 
were used for transport assays. 
 
Liposome preparation 
Large unilamellar liposomes (LUV) were prepared from L-α-phosphatidylcholine from 
egg yolk (egg-lecithin, Cat. No. 61755; Sigma-Aldrich Co., Saint Louis, Missouri, 
USA). Appropriate amount of lipids, dissolved in chloroform-methanol (9:1) mixture, 
was dried as a thin film on the wall of a glass tube under argon stream and the traces of 
the organic solvents was further removed in a vacuum desiccator at 2 Hg mm for 30 
min. Multilamellar liposomes were prepared at 40° C in 20 mM Hepes buffer (pH 7.5) 
supplemented with 10 mM GSH in a lipid concentration of 20 mg/ml. LUV were 
obtained by extrusion of the multilamellar vesicle suspension through a polycarbonate 
filter (pore size 0.4 µm, Nuclepore Track-Etch Membrane; Whatman International Ltd.; 
Maidstone, Kent, UK). At least 40 extrusion cycles were performed at 40o C (the 
extruder and the filters were purchased from Avanti Polar Lipids Inc. Alabaster, 
Alabama USA). Proteoliposomes were prepared from and transport experiments were 
performed on freshly prepared LUVs. For the preparation of proteoliposomes 5 µl of 
liposomes (20 mg L-α-phosphatidylcholine/ml) was fused with 10 µl of in vitro 
translated GLUT10 protein or 60 µg of microsomal protein. 
 
In vitro translation of GLUT10 transporter 
Human SLC2A10 gene was amplified from GLUT10 vector (pLenti-suCMV-
hSLC2A10, Rsv RFP-Puro, 150 ng/µl, Amsbio) by PCR using primers 
5’TACTTCCAATCCAATGCAATGGGCCACTCCCCACCT3’ and 
5’TTATCCACTTCCAATGCATCAGGAGGCCGCAGAGAT3’. The PCR product 
was transferred into pEU3-NII-GLICNot vector by ligation-independent cloning. The 
vector construct is a modification of wheat germ translation vector [28] and codes the 
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recombinant protein with TEV protease cleavable GST affinity tag. E. coli competent 
cells were transformed with these GLUT10 possessing vectors. Plasmid purified from 
ampicillin-resistant colony was sequenced to confirm the PCR accuracy.   
The in vitro mRNA synthesis was accomplished by addition 1 µg purified, NotI 
linearized vector following the provided manual of the kit (TranscriptAid T7 High 
Yield Transcription Kit, Thermo Scientific). The reaction was incubated for 2 h at 37° C 
and then precipitated by ammonium acetate/ethanol mixture. The mRNA pellet was 
washed with absolute ethanol, air-dried and dissolved in SUB-AMIX buffer of cell-free 
translation. 
The batch-wise translation mixture contained 5 µl wheat germ extract (Cell Free 
Sciences), 1 µg mRNA, 5 µl liposome (20 mg/ml), 0.8 µl creatine kinase (1 mg/ml) and 
was completed to 25 µl final volume with 1x SUB-AMIX solution [29]. The reaction 
was incubated at room temperature for 3 h. The control reactions were set up either 
without liposome or exogenous mRNA. The reaction mixtures were centrifuged at 
13000 rpm for 30 min and both the supernatant and the pellet were analyzed by Western 
blot. It was observed that the presence of liposomes resulted in more effective 
translation and less aggregation of GLUT10 protein. 
 
Transport assays 
The uptake/transport of DAA, AA and other compounds was investigated by a rapid 
filtration method with trace amount of radiolabeled compounds as described previously 
[13]. Intact and plasma membrane-permeabilized cells incubated in the presence of the 
indicated ligands and their radiolabeled analoges for the indicated times were filtered  
through glass fiber paper GF/C; 2,5 cm; pore size 0.45 µm (Whatman International Ltd.; 
Maidstone, Kent, UK). Filters were washed with 2 ml of the medium and the 
radioactivity retained on the filter was measured by liquid scintillation counting. In each 
experiment, deoxycholate (0.4% final concentration) was added at the end of the 
incubations; the radioactivity not released by this maneuver was regarded as binding 
and was subtracted from the measured values.  
Transport into microsomes and proteoliposomes was measured by the same method as 
described in details earlier [13]. Since the yield of microsomal fraction was poor from 
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fibroblasts, microsomal vesicles were fused with liposomes and transport assays were 
performed on the resulting chimeric vesicles.  
The following radiolabeled compounds were used in the experiments: D-[U-
14C]Glucose; (Cat. No.: CFB2); Amersham Biosciences UK Ltd.; Little Chalfont, 
Buckinghamshire, UK; [U-14C]Sucrose; (Cat. No.: CFB146); Amersham Biosciences 
UK Ltd.; Little Chalfont, Buckinghamshire, UK; Uridine Diphosphate Glucuronic Acid, 
[Glucuronyl-U-14C]; (Product No.: NEC414010UC) Perkin Elmer; Boston, 
Massachusetts, USA; Ascorbic Acid, L-[1-14C]; (Cat. No.: ARC1569); Americal 
Radiolabeled Chemicals, Inc.; 101 ARC Drive, Saint Louis, USA. DAA was prepared 
by the bromine oxidation method as reporter earlier [13].  
 
Measurement of AA/DAA by HPLC 
Intra- and extracellular total vitamin C levels (AA + DAA) were determined by HPLC 
[30]. Cells were incubated in the presence of 50 µM AA for 0, 6, 12, 24 hours. After 
incubation, the cells were washed twice with PBS and scraped with rubber policeman in 
25 w/v% metaphosphoric acid solution. To measure AA and DAA together 5 mM DTT 
(final concentration) were added to the samples and they were incubated for 20 min at 
room temperature. Before HPLC measurement, samples were centrifuged at 3000 g for 
10 min. Vitamin C was measured from the clear supernatant. Samples were eluated 
through the column (Teknokroma NUCLEOSIL 100 C18 5 µm, 25x0.46 mm) with 0.1 
M Sodium-Dihydrogene-Phosphate solution (pH 3.1) containing 0.2 mM EDTA. 
Vitamin C content of the medium was determined with the same method. 
 
Results 
 
GLUT10 is a DAA transporter 
In the first set of experiments, DAA transport was measured in GLUT10 containing 
proteoliposomes. GLUT10 protein was produced in an in vitro translational system and 
the protein was incorporated into liposomes to exclude the eventual indirect effects of 
the lack of GLUT10 on DAA transport. The presence of GLUT10 in the 
proteoliposomes was checked by immunoblotting (data not shown). GLUT10-
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containing proteoliposomes efficiently transported DAA in a concentration-dependent 
way (Fig. 1A). Glucose transport was also measurable, while unrelated compounds such 
as UDP-glucuronic acid and sucrose were not transported. A very low AA uptake was 
also observed, which was presumably due to the oxidation of AA to DAA during the 
incubation [14]. Incorporation of microsomal proteins prepared from human control 
fibroblasts into liposomes also promoted the transport of DAA (Fig. 1B). Protein-free 
liposomes did not show transport activities (Fig. 1A). 
 
Silencing of GLUT10 compromises DAA transport 
To demonstrate the involvement of GLUT10 in subcellular DAA transport, a hTERT 
immortalized human fibroblast cell line was silenced for GLUT10 with lentiviral-based 
silencing vectors. Stable clones expressing the silencing vector were selected and were 
checked for the efficiency of silencing. Semi-quantitative RT-PCR analysis of the stable 
clones showed that two silencing constructs out of three were effective (Fig. 2A). 
Immunoblotting of cell homogenates revealed that only one of the constructs decreased 
effectively GLUT10 at protein level (Fig. 2B). Measurement of DAA transport on 
plasma membrane permeabilized hTERT immortalized human fibroblasts showed that it 
was severely decreased in these efficiently silenced cells (Fig. 2C). Strict correlation (R2 
values between 0.8859 and 0.9967) was observed when DAA transport activities were 
plotted against GLUT10 protein levels detected by Western blot in silenced fibroblasts 
(Fig. 2D). 
 
DAA transport through endomembranes is defective in ATS 
The uptake of DAA and its reduced form AA was investigated in intact human 
fibroblasts from healthy controls and ATS patients.  Decreased DAA (Fig. 3A) and 
unchanged AA transport (Fig. 3B) was observed in the patients‘ fibroblasts, indicating a 
DAA-specific failure of vitamin C transport. Investigation of long-term AA uptake and 
accumulation in the presence of physiological AA concentration (50 µM) revealed that 
the steady-state intracellular concentration of AA was set up at a lower level in patients’ 
fibroblasts comparing with the controls (Fig. 3C). 
To estimate the transport through endomembranes, the plasma membrane of the cells 
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was selectively permeabilized. An even more dramatic decrease in DAA transport was 
found in cells from ATS patients under this condition, which indicated that the failure is 
due to a transporter resident in the endomembranes (Fig. 3D). AA transport was similar 
in permeabilized control and patient fibroblasts (Fig. 3E). 
 
Re-expression of GLUT10 in ATS fibroblasts restores DAA transport 
GLUT10 expression vector (pG10) and empty cloning vector (mock) were stably 
transfected in the skin fibroblasts of an ATS patient (P1). P1 was intentionally used in 
the reexpression experiments to avoid any interference with an eventual mutated protein 
present in the ATS fibroblasts, since the almost complete lack of GLUT10 mRNA, due 
to activation of nonsense-mediated mRNA decay. These transfected cells do not only 
reexpress GLUT10, but also rescue a control-like phenotype concerning the 
extracellular matrix homeostasis and GLUT10-dependent canonical signal transduction 
mechanisms, as shown in [25]. Absence of the immunoreactivity of GLUT10 was 
observed in non-transfected (Fig. 4B) and mock-transfected (Fig. 4C) cells. Re-
expression of GLUT10 in patients‘ fibroblasts resulted in the appearance of GLUT10 
immunoreactivity as revealed by immunocytofluorescence (Fig. 4D; for comparison see 
control fibroblasts, Fig. 4A). Re-expression also restored the impaired DAA transport 
activity in plasma membrane permeabilized cells (Fig. 4E). 
 
Discussion 
 
Although mutations in the SLC2A10 gene encoding the GLUT10 protein have been 
unequivocally identified as the genetic cause of ATS, the underlying pathogenetic 
mechanisms have not been elucidated up to now. The determination of the intracellular 
localization of GLUT10 and the identification of the ligand(s) it transports are crucial 
for further clarifying the role of GLUT10 in cardiovascular development. The results 
that we obtained demonstrate that GLUT10 is a DAA transporter, and DAA transport is 
defective through the endomembranes of ATS fibroblasts. 
We demonstrated, by incorporating of in vitro translated GLUT10 protein into 
liposomes that it acts as a specific DAA/glucose transporter. Incorporation of 
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microsomal proteins from control and ATS fibroblasts into liposomes showed that DAA 
transport was reduced in proteoliposomes containing patients’ microsomal proteins. In 
plasma membrane permeabilized cells a huge decrease of DAA transport of ATS 
patients’ skin fibroblasts was observed, indicating the defect of DAA transport through 
the endomembranes. The deficient transport was restored by the re-expression of 
GLUT10 in ATS fibroblasts. Moreover, silencing of GLUT10 in hTERT fibroblasts 
also compromised DAA transport through the endomembranes.  
The finding that GLUT10 acts as a DAA transporter is supported by some previous 
observations. The human phenotype of ATS could not be reproduced in GLUT10 
mutant mice, as these mice showed minimal or no pathological signs [11,12]. The 
absence of a relevant phenotype in mice could be explained by the fact that mice, in 
contrast to humans, possess gulonolactone oxidase activity. Thus, mice are able to 
synthesize AA, independently of dietary intake. 
It may be hypothesized that in AA-synthesizing species an enhanced AA production can 
compensate somehow for the reduced activity of organellar AA/DAA transporters. This 
hypothesis is reinforced by the relevant cardiovascular abnormalities that have been 
identified in a zebrafish ATS model [31]. This and other teleost species, like humans, 
lack a functional gulonolactone oxidase gene. 
A glucose transporter in the endomembranes, especially in the ER has long been 
hypothesized as a component of the ER-localized glucose-6-phosphatase system [18]. 
The presence of GLUT10 in the endomembranes as a DAA and glucose transporter can 
be the molecular background of the functionally already observed transport activities 
[19,20,32]. However, it is probable that GLUT10 is not a single DAA/glucose 
transporter in the endomembranes. Functional studies indicated the heterogeneity of 
glucose transport in the ER [19,20]. Moreover, it was also demonstrated that various 
GLUT transporters can sufficiently mediate glucose transport en route from the ER to 
the plasma membrane [21]. These circumstances may provide an explanation for the 
fact that GLUT10 deficiency does not affect similarly all cell types.  
The question arises: which function of DAA/AA is missing in the secretory 
compartment and/or nucleoplasm in ATS patients? Besides the general antioxidant role, 
AA acts also as a cofactor for 2-oxoglutarate/Fe2+ dependent dioxygenases [33]. Prolyl- 
and lysyl-hydroxylases involved in the posttranslational modification of collagen and 
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other extracellular matrix proteins, such as elastin, belong to this group of the enzymes 
[34], as many nucleoplasmic DNA and histone demethylases [35]. DAA has been 
nominated as an electron acceptor in the process of oxidative protein folding, i.e. in the 
formation of disulfide bonds [15,36]. Thus, shortage of AA in the nucleoplasm and in 
the lumenal compartments of the secretory pathway can depress the production of 
extracellular matrix proteins at both epigenetic and posttranslational levels [22]. Indeed, 
changes of gene expression has been demostrated by a  recently published transcriptome 
analyses in ATS fibroblasts. The alterations affected the expression of several genes 
involved not only in TGFβ signaling and extracellular matrix organization and 
homeostasis, but also in specific pathways that control cell energy balance and the 
oxidative stress response [25]. Although further studies are needed to clarify the role of 
these changes in the pathogenesis of ATS, the results presented here clearly show that 
GLUT10 can mediate the membrane transport of DAA and this transport is defective in 
the endomembranes of ATS fibroblasts. 
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Figure legends 
 
Figure 1.  
GLUT10 protein acts as a DAA/glucose transporter in proteoliposomes 
(A) GLUT10 protein was produced by an in vitro translation method and was 
incorporated into liposomes. Transport activities were measured by a rapid filtration 
method and radiolabelled ligands. The following ligands were used (in 1 mM 
concentration if not indicated otherwise): DAA (); DAA 5 mM (); AA (); glucose 
(); UDP-glucuronic acid (); sucrose (). Transport of protein-free liposomes with 1 
mM DAA was also measured (). (B) DAA transport (1 mM) was measured in 
proteoliposomes gained by the fusion of microsomes prepared from the fibroblasts of 
healthy controls () and ATS patients P4 and P7 () with liposomes. Results are 
expressed as means ± SEM of four experiments or (where SEM bars are missing) as 
means of two measurements. 
 
Figure 2. 
Silencing of GLUT10 in hTERT immortalized human fibroblasts decreases DAA 
transport through the endomembranes 
Silencing of GLUT10 in human hTERT fibroblasts were executed with lentiviral-based 
silencing vectors expressing three different shRNA sequences. Out of the three 
constructs, two (shRNAII and shRNAIII) were proven to be effective in silencing the 
transporter with RT-PCR analyses (A). Effective silencing was also verified by 
immunoblotting at protein level (B). Right panel shows one representative Western blot 
out of four; the result of densitometric analysis is presented on the left panel. GAPDH is 
used as housekeeping marker. Examination of DAA uptake (1 mM) in mock silenced 
and effectively silenced cell lines was performed with rapid filtration technique (C). 
DAA transport significantly decreased in both cell lines that were effectively silenced. 
Results are expressed as means ± SEM of 5-10 experiments. Correlation between 
GLUT10 protein levels and DAA transport activities in mock silenced and effectively 
silenced cell lines is shown in (D). Data are taken from panels B and C. Asterisks mark 
statistically significant differences from mock transfected (∗p < 0.05; ∗∗p< 0.01). 
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Figure 3. 
DAA transport through endomembranes is defective in ATS 
DAA (A) and AA (B) uptake was measured in intact control (empty circles) and ATS 
fibroblasts (black circles) by using a rapid filtration method and radiolabeled ligands (1-
1 mM). Panel C shows the long-term uptake of 50 µM AA in fibroblasts, measured by 
HPLC. DAA (D) and AA (E) uptake (1-1 mM) was also measured in plasma membrane 
permeabilized control and ATS fibroblasts by using the rapid filtration method and 
radiolabeled ligands (1-1 mM). Fibroblasts from P1, P3, P4, P5, P7 and P8 (panels A, 
B, D, E) or from P3, P4, P7 and P8 (panel C) were used. Results are expressed as means 
± SEM of 6-10 experiments or (where SEM bars are missing) as means of two 
measurements. 
 
Figure 4. 
Expression of GLUT10 in ATS fibroblasts restores DAA transport 
Stable transfection of GLUT10 into the fibroblasts of the ATS patient P1 resulted in the 
appearance of GLUT10 protein in the cells, as it was verified by immunocytochemistry. 
A, control fibroblasts; B, ATS fibroblasts; C, ATS fibroblasts, mock transfected; D: 
pG10-transfected ATS fibroblasts. DAA (1 mM) transport activity could be measured in 
plasma membrane permeabilized, GLUT10 re-expressing cells (panel E; empty circles, 
means ± SEM of three experiments). In panel E, the DAA uptake in permeabilized ATS 
fibroblasts, shown in Figure 3D, is also reported for comparison (black circles). 
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